Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - prelimary results
Assessment of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia treated in the Department of Haematooncology and Bone Marrow Transplantation of the Medical University in Lublin - prelimary results
Introduction. Despite significant recent advances in the treatment of chronic lymphocytic leukaemia (CLL), most cases of
the disease are still incurable. Treatment with monoclonal antibodies, such as ofatumumab, is one of the new therapeutic
options.
Objective. Retrospective analysis of the efficacy of ofatumumab in patients with chronic lymphocytic leukaemia (CLL)
treated in the Haematooncology and Bone Marrow Transplantation Department of the Medical University of Lublin, Poland,
during 2011–2013.
Materials and method. The analysis included 5 patients (3 women and 2 men), aged 47–65, with Rai stage II-IV CLL, after
a few lines of treatment. Three patients received ofatumumab in monotherapy and 2 patients received ofatumumab in
combination with cyclophosphamide (50 mg/day) and dexamethasone (40 mg/day). All patients included in the study were
diagnosed with an active form of leukaemia with symptoms such as lymphocytosis or massive lymphadenopathy.
Results. All patients responded to the treatment. Within the first 8 weeks of the treatment, levels of white blood cells
returned to normal in patients with baseline lymphocytosis (3 patients). An increase in platelet levels was reported in 3
patients. Haemoglobin levels were higher or comparable to the baseline values in all studied patients after the completion
of immunotherapy. In the patient with massive lymphadenopathy and hepato- and splenomegaly, the size of the lymph
nodes, spleen and liver decreased and neutrophil levels increased. Time of progression was 5–12 months, and in one patient
partial remission has been maintained. The treatment was well-tolerated in most cases. Asymptomatic neutropenia and
an infection with Candida glabrata were observed.
Conclusions. Ofatumumab may be a new and safe therapeutic option for patients with CLL after a few lines of treatment.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies
Informacja
SZANOWNI CZYTELNICY!
UPRZEJMIE INFORMUJEMY, ŻE BIBLIOTEKA FUNKCJONUJE W NASTĘPUJĄCYCH GODZINACH:
Wypożyczalnia i Czytelnia Główna: poniedziałek – piątek od 9.00 do 19.00